(19)
(11) EP 2 969 002 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.02.2018 Bulletin 2018/08

(45) Mention of the grant of the patent:
10.01.2018 Bulletin 2018/02

(21) Application number: 14779507.4

(22) Date of filing: 07.03.2014
(51) International Patent Classification (IPC): 
A61P 29/00(2006.01)
A61K 31/495(2006.01)
A61P 9/10(2006.01)
 A61K 31/47(2006.01)
A61P 11/00(2006.01)
(86) International application number:
PCT/US2014/021706
(87) International publication number:
WO 2014/164282 (09.10.2014 Gazette 2014/41)

(54)

USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF TRAUMATIC INJURY

VERWENDUNG VON LEVOCETIRIZIN UND MONTELUKAST ZUR BEHANDLUNG TRAUMATISCHER VERLETZUNGEN

UTILISATION DE LEVOCETIRIZINE ET MONTELUKAST DANS LE TRAITEMENT DE BLESSURE TRAUMATIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 13.03.2013 US 201361780336 P

(43) Date of publication of application:
20.01.2016 Bulletin 2016/03

(60) Divisional application:
17205910.7

(73) Proprietor: Inflammatory Response Research, Inc.
Santa Barbara CA 93103 (US)

(72) Inventor:
  • MAY, Bruce, Chandler
    Santa Barbara, CA 93111 (US)

(74) Representative: Zacco Sweden AB 
P.O. Box 5581
114 85 Stockholm
114 85 Stockholm (SE)


(56) References cited: : 
WO-A1-2011/159821
WO-A2-2011/041462
US-A1- 2013 030 000
 WO-A1-2013/012199
WO-A2-2012/064301
US-A9- 2012 040 892
   
  • Yu Gl ET AL: "Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. - PubMed - NCBI", , 1 January 2005 (2005-01-01), XP055289974, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pubmed/154 52361?dopt=Abstract [retrieved on 2016-07-20]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).